Skip to main content
Premium Trial:

Request an Annual Quote

Dante Labs Acquires Cambridge Cancer Genomics

NEW YORK — Dante Labs said on Wednesday that it has acquired UK-based cancer informatics firm Cambridge Cancer Genomics, or CCG, for an undisclosed amount.

Additional terms of the deal were not disclosed.

According to New York City-based Dante Labs, the acquisition will bring together its CE-IVD-marked Immensa Genomics Interpretation Software, which enables the interpretation of whole-genome sequencing data in a clinical setting, with CCG's artificial intelligence-based OncOS precision oncology software.

About a year ago, Dante Labs and CCG began working together with Nonacus to build a high-throughput cancer sequencing and interpretation service for tumor profiling.